Elsa G Shapiro

List of Publications by Year
in descending order

74	4,138	136950 32	114465 63
papers	citations	h-index	g-index

82	82	82	2910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I. Molecular Genetics and Metabolism, 2022, 135, 122-132.	1.1	5
2	Quantifying medical manifestations in hurler syndrome with the infant physical symptom score: Associations with long-term physical and adaptive outcomes. Molecular Genetics and Metabolism, 2022, , .	1.1	2
3	Can serial cerebral <scp>MRIs</scp> predict the neuronopathic phenotype of <scp>MPS II</scp>?. Journal of Inherited Metabolic Disease, 2021, 44, 751-762.	3.6	3
4	The natural history of neurocognition in MPS disorders: A review. Molecular Genetics and Metabolism, 2021, 133, 8-34.	1.1	43
5	A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A. Molecular Genetics and Metabolism, 2021, 134, 175-181.	1.1	4
6	Pediatric Neuropsychology and Pediatric Neurology: Kenneth Swaiman's Legacy. Pediatric Neurology, 2021, 122, 122-124.	2.1	0
7	Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A. Molecular Genetics and Metabolism, 2021, 134, 317-322.	1.1	4
8	Therapy development for the mucopolysaccharidoses: Updated consensus recommendations for neuropsychological endpoints. Molecular Genetics and Metabolism, 2020, 131, 181-196.	1.1	26
9	Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter) Tj ETQq1 1 0.784314 rgBT /Overlo Metabolism Reports, 2020, 24, 100630.	1.1	16
10	A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation. Molecular Genetics and Metabolism Reports, 2019, 20, 100484.	1.1	3
11	Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data. Orphanet Journal of Rare Diseases, 2019, 14, 168.	2.7	22
12	Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I. Neurology, 2019, 92, e2321-e2328.	1.1	9
13	Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial. Molecular Genetics and Metabolism, 2019, 126, 121-130.	1.1	37
14	Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genetics in Medicine, 2018, 20, 1423-1429.	2.4	54
15	Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B. Journal of Pediatrics, 2018, 197, 198-206.e2.	1.8	29
16	Observing the advanced disease course in mucopolysaccharidosis, type IIIA; a case series. Molecular Genetics and Metabolism, 2018, 123, 123-126.	1.1	18
17	Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome. Orphanet Journal of Rare Diseases, 2018, 13, 76.	2.7	18
18	Selecting measures for the neurodevelopmental assessment of children in low- and middle-income countries. Child Neuropsychology, 2017, 23, 1-42.	1.3	53

#	Article	IF	Citations
19	Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. American Journal of Medical Genetics, Part A, 2017, 173, 780-783.	1.2	26
20	Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy. JAMA Neurology, 2017, 74, 710.	9.0	55
21	Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure. Molecular Genetics and Metabolism, 2017, 121, 70-79.	1.1	35
22	Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: A review of the literature. Molecular Genetics and Metabolism, 2017, 121, 57-69.	1.1	20
23	Previously unrecognized behavioral phenotype in Gaucher disease type 3. Neurology: Genetics, 2017, 3, e158.	1.9	10
24	Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses. Molecular Genetics and Metabolism, 2017, 122, 8-16.	1.1	44
25	Practical management of behavioral problems in mucopolysaccharidoses disorders. Molecular Genetics and Metabolism, 2017, 122, 35-40.	1.1	34
26	Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III. Orphanet Journal of Rare Diseases, 2017, 12, 117.	2.7	27
27	Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations â€" Neurological signs and symptoms. Molecular Genetics and Metabolism, 2017, 122, 1-7.	1.1	119
28	Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Molecular Genetics and Metabolism Reports, 2017, 13, 64-68.	1.1	18
29	Long-term Behavioral Problems in Children With Severe Malaria. Pediatrics, 2016, 138, e20161965.	2.1	33
30	Elevated TNF-Î± is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Molecular Genetics and Metabolism, 2016, 117, 427-430.	1.1	36
31	The neurobehavioral phenotype in mucopolysaccharidosis Type IIIB: An exploratory study. Molecular Genetics and Metabolism Reports, 2016, 6, 41-47.	1.1	35
32	A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA. Journal of Pediatrics, 2016, 170, 278-287.e4.	1.8	91
33	Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism, 2016, 118, 65-69.	1.1	28
34	A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Molecular Genetics and Metabolism Reports, 2016, 7, 32-39.	1.1	32
35	Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Molecular Genetics and Metabolism Reports, 2016, 7, 27-31.	1.1	20
36	Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood, 2015, 125, 2164-2172.	1.4	262

#	Article	IF	Citations
37	Quantifying behaviors of children with Sanfilippo syndrome: The Sanfilippo Behavior Rating Scale. Molecular Genetics and Metabolism, 2015, 114, 594-598.	1.1	31
38	Clinical outcomes of Hurler syndrome treated exclusively with enzyme replacement therapy from a young age. Molecular Genetics and Metabolism, 2015, 114, S40.	1.1	2
39	Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2015, 114, 170-177.	1.1	43
40	Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. Molecular Genetics and Metabolism, 2015, 116, 61-68.	1.1	59
41	Diffusion tensor imaging and myelin composition analysis reveal abnormal myelination in corpus callosum of canine mucopolysaccharidosis I. Experimental Neurology, 2015, 273, 1-10.	4.1	14
42	Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. Journal of Pediatric Rehabilitation Medicine, 2014, 7, 159-165.	0.5	19
43	Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the Î±-L-iduronidase gene in Hurlerâ€“Scheie syndrome. Molecular Genetics and Metabolism, 2014, 111, 123-127.	1.1	26
44	Severe Malarial Anemia is Associated With Long-term Neurocognitive Impairment. Clinical Infectious Diseases, 2014, 59, 336-344.	5.8	107
45	Acquired Autistic Behaviors in Children with Mucopolysaccharidosis Type IIIA. Journal of Pediatrics, 2014, 164, 1147-1151.e1.	1.8	41
46	Carotid intimaâ€“media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Molecular Genetics and Metabolism, 2014, 111, 128-132.	1.1	25
47	Mucopolysaccharidosis Type IIIA presents as a variant of KlÃ¼verâ€“Bucy syndrome. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 608-616.	1.3	29
48	Enzyme Replacement is Associated with Better Cognitive Outcomes after Transplant in Hurler Syndrome. Journal of Pediatrics, 2013, 162, 375-380.e1.	1.8	58
49	Methods of Neurodevelopmental Assessment in Children with Neurodegenerative Disease: Sanfilippo Syndrome. JIMD Reports, 2013, 13, 129-137.	1.5	47
50	Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I. Comparative Medicine, 2013, 63, 163-73.	1.0	23
51	An exploratory study of brain function and structure in mucopolysaccharidosis type I: Long term observations following hematopoietic cell transplantation (HCT). Molecular Genetics and Metabolism, 2012, 107, 116-121.	1.1	36
52	The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Molecular Genetics and Metabolism, 2007, 91, 37-47.	1.1	172
53	The Color Object Association Test (COAT): The Development of a New Measure of Declarative Memory for 18- to 36-Month-Old Toddlers. Child Neuropsychology, 2007, 14, 21-41.	1.3	27
54	Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human Î±-<scp>l</scp>-Iduronidase (Laronidase). Pediatrics, 2007, 120, e37-e46.	2.1	216

#	Article	IF	Citations
55	Long-term Outcomes of Adaptive Functions for Children with Mucopolysaccharidosis I (Hurler) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Behavioral Pediatrics, 2006, 27, 290-296.	1.1	61
56	Measurement of Vigilance in 2-Year-Old Children. Developmental Neuropsychology, 2004, 25, 227-250.	1.4	52
57	Effective treatment of Î±-mannosidosis by allogeneic hematopoietic stem cell transplantation. Journal of Pediatrics, 2004, 144, 569-573.	1.8	62
58	Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood, 2004, 104, 881-888.	1.4	334
59	Measuring developmental outcomes of lead exposure in an urban neighborhood: the challenges of community-based research. Journal of Exposure Science and Environmental Epidemiology, 2000, 10, 732-742.	3.9	11
60	Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Current Opinion in Neurology, 1999, 12, 167-176.	3.6	249
61	Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Current Opinion in Hematology, 1999, 6, 377.	2.5	117
62	Hurler syndrome: Past, present, and future. Journal of Pediatrics, 1998, 133, 7-9.	1.8	44
63	Hematopoietic Stem-Cell Transplantation in Globoid-Cell Leukodystrophy. New England Journal of Medicine, 1998, 338, 1119-1127.	27.0	308
64	Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children. Blood, 1998, 91, 2601-2608.	1.4	323
65	The Pediatric Neuropsychologist Introduction to the Special Section. Child Neuropsychology, 1997, 3, 226-226.	1.3	0
66	THE PEDIATRIC NEUROPSYCHOLOGIST Training Issues in Pediatric Neuropsychology. Child Neuropsychology, 1997, 3, 227-229.	1.3	3
67	Minnesota Preschool Affect Rating Scales: Development, Reliability, and Validity. Journal of Pediatric Psychology, 1994, 19, 325-345.	2.1	15
68	CSF findings in adrenoleukodystrophy: Correlation between measures of cytokines, IgG production, and disease severity. Pediatric Neurology, 1994, 10, 289-294.	2.1	15
69	Dementia in Childhood: Issues in Neuropsychological Assessment with Application to the Natural History and Treatment of Degenerative Storage Diseases. Advances in Child Neuropsychology, 1994, , 119-171.	0.3	14
70	Processing of emotional information in children with attentionâ€deficit hyperactivity disorder. Developmental Neuropsychology, 1993, 9, 207-224.	1.4	62
71	White matter dysfunction and its neuropsychological correlates: A longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 610-624.	1.1	31
72	Treatment of Late Infantile Metachromatic Leukodystrophy by Bone Marrow Transplantation. New England Journal of Medicine, 1990, 322, 28-32.	27.0	151

#	Article	IF	Citations
73	Hemi-Inattention Resulting from Left Hemisphere Brain Damage During Infancy. Cortex, 1986, 22, 279-287.	2.4	23
74	Neurological findings and the Kaufman assessment battery for children. Developmental Neuropsychology, 1986, 2, 51-64.	1.4	3